NTRK1 and neoplasm: It has been revealed that knock out of the IL-8 receptor, CXCR2, by CRISPR/Cas9 in triple-negative breast cancer cell lines reduces the progression of the tumor (112); and (VI) Tumor-Secreted Protein S (Pros1) is the best-studied ligand of Tyro3/Axl/Mer (TAM) receptor tyrosine kinases, and its CRISPR-based deletion inhibits M2 polarization, leading to heightened immune infiltration and reduced tumor viability (113).